1 / 15

The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC)

The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC). Joe V Selby MD, Director DMCRC Coordinating Center Kaiser Permanente Northern CA. Diabetes Multi-Center Research Consortium (DMCRC). Coordinating Center HMO Research Network DEcIDE Center

jereni
Download Presentation

The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC) Joe V Selby MD, Director DMCRC Coordinating Center Kaiser Permanente Northern CA

  2. Diabetes Multi-Center Research Consortium (DMCRC) • Coordinating Center • HMO Research Network DEcIDE Center • PI Joe Selby, MD • Co-PI Patrick O’Connor MD • Affiliate Center • Johns Hopkins University DEcIDE Center • PI Jodi Segal, MD • Co-PI Eric Bass, MD • AHRQ Project Officers • Barbara Bartman, MD MPH • Scott Smith, R.Ph., M.S.P.H., Ph.D.

  3. DMCRC – 1 Expanded Executive Committee • Also includes: • VanderbiltDEcIDE Center – Marie Griffin MD, PI – Comparative Effectiveness of Oral Agents in Type 2 Diabetes • RTIDEcIDE Center – Suzanne West Ph.D. PI – Comparative Effectiveness of Oral Hypoglycemics on Chronic Kidney Disease and on Time to Initiation of Maintenance Insulin

  4. Formation and Composition of DMCRC Stakeholders’ Committee • Formation: June 2009 • Composition: • Expanded DMCRC Executive Committee • Government Agencies – AHRQ, NIDDK, CMS, FDA, CDC, VA • Clinicians – ACP,AAFP, AADE • Patients - ADA, individual patient rep.

  5. Purpose of the DMCRC Stakeholders’ Committee • To represent various constituencies and perspectives in a process of nominating and prioritizing topics for AHRQ-funded, empirical CER. • To review AHRQ-funded diabetes-related CER and provide input on: • Interpretation • Dissemination • Future Questions

  6. Timeline of DMCRC Stakeholders’ Meetings First Face-to-Face Meeting June 16, 2009 First Tele- Conference Feb 17, 2010 Second Face-to-face Meeting July 1, 2010 2009 2010 Initial Topic Nominations And Prioritization Focus on Treatment Focus on DM Prevention Review Ongoing CER Research Topic Re-prioritization for Both treatment and Prevention

  7. Format of DMCRC Stakeholders’ Meetings • Greetings and Update from AHRQ ~30 min • Presentation/Discussion of Research ~3 hrs • Findings from CER Work of Consortium members • Review of recent clinical trials findings/implications • Nominations for Topics ~ 2 hrs • All participants invited to offer nominations • Time for Brief Presentations • Voting ~ 30 min • assessing preferences of Stakeholders vs. EC • Brief Review of Results and Next Steps ~ 30 min

  8. Secrets of the SauceDMCRC Stakeholders’ Committee • Meticulous planning with facilitator • Clear goals and game plan • Leave plenty of time for discussion • Facilitator to keep group on track, pull quiet ones out, chair topic nomination segment • Acknowledge relevant work of stakeholders • Demonstrate consequences of prior decisions and prioritization – i.e., funded projects

  9. Stakeholder Prioritized Listof CER Questions on Treatment • Compare 2nd line therapies for their long-term effects (e.g., CVD endpoints) – 19 votes • Compare system approaches to coordinated care vs. usual care – 15 votes • Evaluate strategies to remove barriers to self care (including cost barriers) – 15 votes • Compare various providers and sites for providing behavior change support – 12 votes • Compare strategies for supporting insulin initiation – 9 votes • Compare system-level strategies for supporting adherence to medications – 9 votes

  10. Stakeholder Prioritized Listof CER Questions on Prevention • Compare strengthened linkages between primary care and community resources vs. enhancing primary care to address overweight, lifestyle change – 25 votes • What are effective strategies for counseling patients in the primary care setting for weight loss? (Including issues of coverage) – 21 votes • Compare various approaches to GDM prevention and/or prevention of T2 DM in women with GDM. – 10 votes

  11. Keeping Stakeholders Engaged • Emphasizing the funding by AHRQ of projects that address previously prioritized topics • Presenting and discussing findings from studies they recommended be done • Incorporating their comments and responses into ongoing analyses or taking their suggestions and designing next generation protocols • Identify effective, affordable (“Chevrolet”) programs to support individual behavior change – 10 votes

  12. Challenges • Addressing or managing Stakeholder priority topics not squarely in COE purview • Prevention • Systems-level approaches • Engaging with community • Staying on top and keeping Stakeholders on top of all the research that AHRQ is funding • Adding stakeholders from delivery systems, possibly from industry

  13. Next Steps Executive Committee – Includes AHRQ, Coordinating, Affiliate Center Leadership Project Manger Data Committee Methods Committee Clinical Committee Stakeholder Committee

  14. Next Steps Executive Committee – Includes AHRQ, Coordinating, Affiliate Center Leadership Project Manger Data Committee Methods Committee Clinical Committee Stakeholder Committee

  15. Next Steps Executive Committee – Includes AHRQ, Coordinating, Affiliate Center Leadership Project Manger Data Committee Methods Committee Clinical Committee Stakeholder Committee

More Related